View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
August 9, 2012

TiGenix completes enrolment in Phase IIa rheumatoid arthritis study

TiGenix, a European cell therapy company, has completed patient enrolment in a Phase IIa rheumatoid arthritis (RA) study of Cx611.

TiGenix, a European cell therapy company, has completed patient enrolment in a Phase IIa rheumatoid arthritis (RA) study of Cx611.

Cx611 is a suspension of expanded allogeneic adult stem cells derived from human adipose tissue, delivered through intravenous injection for the treatment of RA.

TiGenix CEO Eduardo Bravo said that, in addition to the primary endpoints of safety and optimal dosing, the company expects the trial to indicate the period of effectiveness of Cx611 in patients who have failed to respond previous treatments.

"In the trial patients are treated with three injections of Cx611. The six-month follow-up without further dosing should provide us with a truly meaningful result," Bravo said.

"This is the most advanced stem cell therapy trial in RA in the world, and completing the enrollment on time confirms our leadership position in the field."

The Phase IIa multicentre, placebo-controlled trial has enrolled 53 patients. They will be divided into three groups with different dosing regimens.

The objective of the Phase IIa RA study is to determine safety, feasibility, tolerance, and optimal dosing.

The study is being conducted at 23 centres and the company expects the final results to be available in the first half of 2013.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena